Sinovac Biotech Ltd.

Chinese biopharmaceutical company with Singapore presence, specialized in R&D, manufacturing and commercialization of vaccines against human infectious diseases. Developed CoronaVac® (COVID-19 vaccine), approved in over 60 countries. Portfolio includes vaccines against hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease and hand-foot-mouth disease (EV71). Discontinued CoronaVac in January 2024.